Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Medicare Rx Benefit Cited As Top Priority By Incoming Senate Leader Frist

Executive Summary

Adding a prescription drug benefit to Medicare will be one of incoming Senate Majority Leader Bill Frist's (R-Tenn.) top priorities in the 108th Congress

You may also be interested in...

Medicare Rx “Tripartisan” Group Backing Away From $400 Bil. Cost

Proposals for a Medicare prescription drug benefit should increase the level of beneficiary cost sharing to fit within the available financial resources, Senate Finance Committee health policy director Linda Fishman told an Alliance for Health Reform forum Dec. 19 in Washington, D.C

Lilly Says Thimerosal Provision Is Clarification Of Existing Law, Not Change

Thimerosal liability protection included in the Homeland Security legislation is a clarification of existing law rather than a change, Lilly says

Vaccine Definition Refined In Homeland Security Bill To Include Thimerosal

Vaccines are defined as including all components and ingredients listed in product license applications under the Homeland Security Act

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts